CHM chimeric therapeutics limited

Ann: CLTX CAR T data shows regional control of tumour recurrence, page-14

  1. 2,998 Posts.
    lightbulb Created with Sketch. 2019
    Hi All,
    I think the SNO conference and subsequent announcements were all that we could have hoped for. I'm in awe of some of the regular posters on this thread and am learning every time I visit it.

    We are sitting on a MC of 100 million which in my very amateur opinion, is not bad for a small Oz bio with a single Phase 1 trial running, so the good news may already be reflected in the sp. I'm happy to defer to other better informed posters though.

    Possibly no more results until well into 2022 so we may continue to float around the early 30s for a while. The management team is well credentialed but isn't cheap so hopefully no Cap Raises until late next year when the SP will be higher.

    Very excited, I'm sure a lot of the movers and shakers at the SNO conference will be watching.


    Pete
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
0.4¢
Change
0.000(0.00%)
Mkt cap ! $8.060M
Open High Low Value Volume
0.4¢ 0.4¢ 0.4¢ $20.21K 5.053M

Buyers (Bids)

No. Vol. Price($)
2 2213046 0.4¢
 

Sellers (Offers)

Price($) Vol. No.
0.5¢ 13563373 20
View Market Depth
Last trade - 15.01pm 24/06/2025 (20 minute delay) ?
CHM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.